Delay differential equation (DDE) modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Liso-cel) therapies [0.03%]
基于CAR-T细胞动力学的延迟微分方程（DDE）建模：应用于BCMA定向（Ide-cel，Orva-cel）和CD19定向（Liso-cel）疗法
Yiming Cheng,Yan Li
Yiming Cheng
Chimeric antigen receptor (CAR) T-cell therapies undergo rapid in vivo expansion followed by contraction and variable long-term persistence after a single infusion, yielding cellular kinetic (CK) profiles that differ fundamentally from conv...
Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma [0.03%]
一种新型的177Lu-AAZTA5-卡非佐米缀合物的设计、放射标记和生物评价：作为治疗检测多重骨髓瘤蛋白酶体靶向制剂的研究
Mohamed A Gizawy,Fawzy A Marzook,Hanan M El-Shershaby et al.
Mohamed A Gizawy et al.
The development of proteasome-targeted radiopharmaceuticals represents a promising strategy for the treatment of multiple myeloma. In this work, a novel Carfilzomib-based radioconjugate was designed through conjugation with the hybrid chela...
Reply to comment on "Industry guidance on container closure integrity strategies for difficult-to-test parenteral products (DTPs)" [0.03%]
对“难以测试的注射产品(CDPs)容器封闭完整性策略行业指南”的评论回复
Klaus Wuchner,David Riesop,Carine Huon et al.
Klaus Wuchner et al.
Comment on "Industry guidance on container closure integrity strategies for difficult-to-test parenteral products (DTPs)" [0.03%]
对“难以测试的注射产品（DTP）容器密封完整性策略行业指导”的评论
Shweta Sharma,Talha Jawaid,Konda V V S Krishna
Shweta Sharma
Reply to comment on "Multidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals" [0.03%]
对“多学科探索性调查：生物制剂处理和监管观点的初步见解”的评论答复
Mattias Paulsson,Lara Nonis,Stanley Kwok
Mattias Paulsson
Comment on "Multidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals" [0.03%]
对“多学科探索性调查：生物药处置和监管观点的初步见解”的评论
Santosh Bhende,Atul Phatak,Pravin Chaudhari
Santosh Bhende
Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products [0.03%]
已批准的人用药品中二次胺相关杂质亚硝胺药物活性成分相关杂质的模拟研究
Xiang Yu,Jingyue Yang,Ee-Sunn Chia et al.
Xiang Yu et al.
Nitrosamines, recognized as potential carcinogens, have emerged as impurities of concern in pharmaceutical products. This study evaluates the formation risk of active pharmaceutical ingredient (API) fragment nitrosamine drug substance-relat...
A Formal Thank-You to my Postdoctoral Advisor, Richard H. Guy [0.03%]
致博士后导师理查德·盖伊教授的感谢信——兼论他在数论和离散几何领域的工作
Audra L Stinchcomb
Audra L Stinchcomb
Kenneth L Audus
Kenneth L Audus
Small Intestine-Permeable Cyclic Peptide-Mediated Enhancement of Fc-Fusion Protein Absorption in Mice [0.03%]
一种小肠通透的环形多肽及其促进融合蛋白吸收的应用
Shoma Chikamatsu,Kosei Sakaguchi,Koki Sasaki et al.
Shoma Chikamatsu et al.
Fragment crystallizable (Fc)-fusion proteins represent a major class of biologics with extended half-lives via neonatal Fc receptor (FcRn)-mediated recycling. However, their clinical application requires invasive intravenous or subcutaneous...